Natalie Yivgi-Ohana
CEO & Co-founder
Claimed by owner Minovia Therapeutics
Former names:
Mitochondrial Augmentation Cell-therapy Platform
Minovia Therapeutics
www.israel21c.org
•
Feb 1, 2023
New cell therapy may be key to curing disease - ISRAEL21c
www.businesswire.com
•
Oct 1, 2021
Minovia Therapeutics Announces Data from Preclinical Studies Demonstrating that Mitochondrial Augmentation of CD34+ cells Confers Functional Benefit and that Mitochondrial Transfer Occurs Between Hematopoietic Cells In Vivo
www.businesswire.com
•
Jul 30, 2021
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
www.fiercebiotech.com
•
Mar 12, 2021
Mitochondrial biotech Minovia Therapeutics nabs biopharma veteran Jacobs as new chief medical officer
www.businesswire.com
•
Nov 23, 2020
Minovia Therapeutics Announces Manufacturing Partnership with BioSpherix and Appoints David O'Donnell as Global Head of Manufacturing and Supply Chain
www.businesswire.com
•
Nov 9, 2020
Minovia Therapeutics to Participate at Upcoming Credit Suisse Healthcare Conference on November 12th
bostonrealestatetimes.com
•
Jun 15, 2020
Minovia Therapeutics Leases 4,600 SF in Woburn - Boston Real Estate Times
www.biospace.com
•
Jul 16, 2019
New Hope for Rare Mitochondrial Diseases: An Interview With Minovia Therapeutics' Natalie Yivgi Ohana BioSpace
www.biospace.com
•
Jun 26, 2019
Minovia Announces Dosing of Patient in First Mitochondrial Cell Therapy Trial for the Treatment of Pearson Syndrome BioSpace
About
Minovia Therapeutics treats mitochondrial diseases through cell therapy using its Mitochondrial Augmentation Therapy (MAT) platform. The companys initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments.
Following a compassionate use program, the company is accelerating its clinical development and science to bring MAT to those who need it most. Minovia is currently conducting a phase 1/2 clinical trial in patients with Pearson Syndrome.
Following a compassionate use program, the company is accelerating its clinical development and science to bring MAT to those who need it most. Minovia is currently conducting a phase 1/2 clinical trial in patients with Pearson Syndrome.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
Mitochondrial Augmentation Therapy
Geographic markets
United States, Europe, Israel
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
0
Investors
0
News
(9)
www.israel21c.org
•
Feb 1, 2023
New cell therapy may be key to curing disease - ISRAEL21c
www.businesswire.com
•
Oct 1, 2021
Minovia Therapeutics Announces Data from Preclinical Studies Demonstrating that Mitochondrial Augmentation of CD34+ cells Confers Functional Benefit and that Mitochondrial Transfer Occurs Between Hematopoietic Cells In Vivo
www.businesswire.com
•
Jul 30, 2021
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
www.fiercebiotech.com
•
Mar 12, 2021
Mitochondrial biotech Minovia Therapeutics nabs biopharma veteran Jacobs as new chief medical officer
www.businesswire.com
•
Nov 23, 2020
Minovia Therapeutics Announces Manufacturing Partnership with BioSpherix and Appoints David O'Donnell as Global Head of Manufacturing and Supply Chain
www.businesswire.com
•
Nov 9, 2020
Minovia Therapeutics to Participate at Upcoming Credit Suisse Healthcare Conference on November 12th
bostonrealestatetimes.com
•
Jun 15, 2020
Minovia Therapeutics Leases 4,600 SF in Woburn - Boston Real Estate Times
www.biospace.com
•
Jul 16, 2019
New Hope for Rare Mitochondrial Diseases: An Interview With Minovia Therapeutics' Natalie Yivgi Ohana BioSpace
www.biospace.com
•
Jun 26, 2019
Minovia Announces Dosing of Patient in First Mitochondrial Cell Therapy Trial for the Treatment of Pearson Syndrome BioSpace
The Team
(3)
SM
Shai Melcer
Chief Business Officer
NS
Noa Sher
Chief Scientist
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Media gallery
(1)
Locations
Israel
HaSadna 3, Tirat Carmel, Israel
Offices Abroad
Cambridge, Massachusetts, USA
Locations
Israel
HaSadna 3, Tirat Carmel, Israel
Offices Abroad
Cambridge, Massachusetts, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,